Accelerating the biosimilar medicines access journey through benefit-sharing

28 March 2019

Biosimilar medicines have significantly increased equity of access to important […]

Major challenges in the Intellectual Property (IP) environment for pharmaceuticals debated at Medicines for Europe Legal Conference

27 March 2019

The SPC manufacturing waiver, which will put an end to […]

Joint Press Statement of the Inter Associations Initiative (IAI) Pharmaceuticals in the Environment Task Force (AESGP, EFPIA, Medicines for Europe) – European Union Strategic Approach to Pharmaceuticals in the Environment

12 March 2019

Medicines for Europe applauds compromise on SPC manufacturing waiver

14 February 2019

Today, the European Council, Parliament and Commission agreed a compromise […]

New safeguards for patient safety as Falsified Medicines Directive comes into force

8 February 2019

The EU Falsified Medicines Directive was adopted in 2011 to […]

SUPPORT a comprehensive SPC manufacturing waiver: for patient access, sustainable healthcare and manufacturing jobs

7 February 2019

SPC manufacturing waiver cannot be derailed by foreign vested interests

7 February 2019

Medicines for Europe calls on the European Council, Parliament and […]

A shared vision for better regulatory science: – Moving toward the light at the end of the tunnel

31 January 2019

This week in London, Medicines for Europe gathers regulators and […]

Efficient use of pharmacovigilance data essential for patient safety

30 January 2019

National authorities, regulators, industry leaders, and stakeholders gathered in London […]

Competition policy essential for access to medicines

28 January 2019

Medicines for Europe welcomes the publication of the European Commission […]